Stem Cell Ophthalmology Treatment Study

Status unconfirmed · Not applicable

Conditions studied: Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma

In brief

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/

Key facts

Study ID

NCT01920867

Run by

MD Stem Cells

People needed

300

Starts

2012-08-01

Expected to finish

2020-07-01

Last updated by the study team

2019-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have objective, documented damage to the retina or optic nerve unlikely to improve OR
• Have objective, documented damage to the retina or optic nerve that is progressive
• AND have less than or equal to 20/40 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.
• Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.
• If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).
• Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
• Be over the age of 18
• Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.

You may not qualify if…

• Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.
• Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.
• Patients who are not capable of providing informed consent.
• Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.

Where it is running

• MD Stem Cells — Westport, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.